MRRS adds "Frontier Pharma: Parkinson’s Disease – Identifying and Commercializing First-in-Class Innovation" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Parkinson’s Disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease, affecting around 7.4 million people worldwide. It is caused by the progressive loss of dopamine-producing neurons in the substantia nigra within the basal ganglia. The main motor symptoms are tremors, bradykinesia and rigidity, although symptoms vary between individuals. As the disease progresses to more advanced stages, increasing symptoms and complications develop, which can cause severe disability in patients.

The current market offers a number of anti-PD treatment options which provide symptomatic relief. Levodopa is currently the gold standard therapy, with other drug classes including dopamine agonists and Monoamine Oxidase B (MAO-B) inhibitors also used to treat early and advanced cases. With no current treatment showing effectiveness in delaying the course of the disease, PD remains incurable. The high unmet need for a disease-modifying therapy is reflected in the pipeline, where a high proportion of early-stage first-in-class programs target the potential pathogenic mechanisms underlying neurodegeneration.

Table of Contents
1 Table of Contents 2
2 Executive Summary 4
2.1 High Unmet Needs Remain in Parkinson’s Disease Market 4
2.2 Diverse and Innovative Pipeline to Shift Focus to Disease Modification 4
2.3 Deals Landscape Presents Substantial Investment Opportunities 4
3 The Case for Innovation 5
3.1 Growing Opportunities for Biologic Products 6
3.2 Diversification of Molecular Targets 6
3.3 Innovative First-in-Class Product Developments Remain Attractive 6
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 7
3.5 Sustained Innovation 7
3.6 GBI Research Report Guidance 8
4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.2 Epidemiology 9
4.3 Disease Etiology 10
4.3.1 Exposure to Environmental Toxins 10
4.3.2 Genetic Causes of Familial Parkinson’s Disease 10
4.3.3 Susceptibility Genes for Parkinson’s Disease 12
4.4 Disease Pathophysiology 12
4.4.1 Basal Ganglia Anatomy and Physiology 12
4.4.2 Process Underlying Neurodegeneration 15
4.5 Disease Symptoms 19
4.6 Co-morbidities and Complications 19
4.7 Diagnosis 19
4.8 Classification of Disease Stages 20
4.8.1 Hoehn and Yahr Scale 20
4.8.2 Unified Parkinson’s Disease Rating Scale 20
4.8.3 Scale for the Assessment of Positive Symptoms 22
4.8.4 Mini Mental State Examination 22
4.9 Prognosis and Disease Staging 22
4.10 Treatment Options 23
4.10.1 Pharmacotherapy 23
4.10.2 Non-pharmacological Treatment 25......

List of Tables and Figures 
Table 1: Definition of the Stages of Disability in Hoehn and Yahr Scale, 1967 20
Table 2: Evaluation of Disability by Unified Parkinson Disease Rating Scale, 2013 21
Figure 1: Innovation Trends in Product Approvals, 1987-2013 5
Figure 2: Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval, 2006-2013 7
Figure 3: Indirect and Direct Pathways in Basal Ganglia 14
Figure 4: Molecular Targets of Marketed Products 27
Figure 5: Treatment Algorithm of Parkinson’s Disease 28
Figure 6: Efficacy and Safety of Treatments for Early Parkinson’s Disease 30
Figure 7: Efficacy and Safety of Treatments for Advanced Parkinson’s Disease 32
Figure 8: Efficacy and Safety of Treatment for Non-Motor Symptoms in Parkinson’s Disease 33
Figure 9: Developmental Pipeline Overview 36
Figure 10: Parkinson’s Disease Pipeline by Molecular Target 37
Figure 11: Parkinson’s Disease Pipeline by Molecular Target 39
Figure 12: Molecular Target Category Comparison, Pipeline and Marketed Products 40
Figure 13: Molecular Target Category Comparison, Pipeline First-in-Class and Established Molecular Targets 42
Figure 14: Parkinson’s Disease, Global, First-in-Class Pipeline Products 43
Figure 15: First-in-Class Molecular Target Analysis Matrix 48......

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/frontier-pharma-parkinsons-disease-identifying-and-commercializing-first-in-class-innovation-2

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/